^
    Back
    Association details:
    Biomarker:PTEN deletion
    Cancer:Glioblastoma
    Drug:pevonedistat (MLN4924) (NEDD8 activating enzyme inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Neuro Oncol
    Title:

    PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors

    Published date:
    03/19/2022
    Excerpt:
    We report vulnerability to MLN4924 or pevonedistat (a neddylation inhibitor) in a subset of glioblastoma (GBM) preclinical models and identify biomarkers, mechanisms, and signatures of differential response....Loss of PTEN and its nuclear functions is associated with resistance to MLN4924.
    DOI:
    10.1093/neuonc/noac067
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    AACR-II 2020
    Title:

    Loss of PTEN confers resistance to neddylation inhibition through TOP2A in glioblastoma

    Excerpt:
    ...mutations and deletions in phosphatase and tensin homolog (PTEN) are associated with resistance to MLN4924 in both low-grade gliomas and GBM.